Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Employees - 2617,
CEO - Mr. Herve Hoppenot,
Sector - Healthcare,
Country - US,
Market Cap - 12.09B
Altman ZScore(max is 10): 4.54, Piotroski Score(max is 10): 6, Working Capital: $1597183000, Total Assets: $5444322000, Retained Earnings: $-1072881000, EBIT: 174517000, Total Liabilities: $1996694000, Revenue: $4241217000
AryaFin Target Price - $82.01 - Current Price $62.46 - Analyst Target Price $73.79
| Ticker | INCY |
| Index | S&P 500 |
| Curent Price | 62.46 |
| Change | 0.21% |
| Market Cap | 12.09B |
| Average Volume | 1.82M |
| Income | 32.62M |
| Sales | 4.24B |
| Book Value/Share | 17.82 |
| Cash/Share | 11.15 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 2617 |
| Moving Avg 20days | -1.78% |
| Moving Avg 50days | -9.08% |
| Moving Avg 200days | -7.95% |
| Shares Outstanding | 193.43M |
| Earnings Date | Feb 10 BMO |
| Inst. Ownership | 95.51% |
| Price/Earnings | 230.31 |
| Forwad P/E | 9.61 |
| PE Growth | 2.37 |
| Price/Sales | 2.85 |
| Price/Book | 3.50 |
| Price/Cash | 5.60 |
| Price/FCF | 48.53 |
| Quick Ratio | 1.94 |
| Current Ratio | 1.97 |
| Debt/Equity | 0.02 |
| Return on Assets | 0.53% |
| Return on Equity | 0.76% |
| Return on Investment | 0.93% |
| Gross Margin | 91.09% |
| Ops Margin | 1.89% |
| Profit Margin | 0.77% |
| RSI | 40.22 |
| BETA(β) | 0.69 |
| From 52week Low | 24.05% |
| From 52week High | -25.60% |
| EPS | 0.27 |
| EPS next Year | 6.50 |
| EPS next Qtr | 1.04 |
| EPS this Year | 419.33% |
| EPS next 5 Year | 97.13% |
| EPS past 5 Year | -40.36% |
| Sales past 5 Year | 14.56% |
| EPS Y/Y | -88.32% |
| Sales Y/Y | 14.76% |
| EPS Q/Q | 14.62% |
| Sales Q/Q | 16.32% |
| Sales Surprise | 3.39% |
| EPS Surprise | -5.06% |
| ATR(14) | 2.10 |
| Perf Week | 2.93% |
| Perf Month | -10.53% |
| Perf Quarter | -9.57% |
| Perf Year | 11.88% |
| Perf YTD | -9.57% |
| Target Price | 73.79 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer